Aquestive Therapeutics, Inc.
AQST
$4.39
-$0.08-1.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.00% | 1.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.00% | 1.62% | |||
| Cost of Revenue | -40.56% | 29.52% | |||
| Gross Profit | 52.90% | -13.52% | |||
| SG&A Expenses | -66.56% | 115.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -55.44% | 72.34% | |||
| Operating Income | 85.42% | -151.23% | |||
| Income Before Tax | 74.71% | -106.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 74.71% | -106.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 74.71% | -106.27% | |||
| EBIT | 85.42% | -151.23% | |||
| EBITDA | 85.74% | -152.94% | |||
| EPS Basic | 74.85% | -86.97% | |||
| Normalized Basic EPS | 74.83% | -87.06% | |||
| EPS Diluted | 74.85% | -86.97% | |||
| Normalized Diluted EPS | 74.83% | -87.06% | |||
| Average Basic Shares Outstanding | 0.53% | 10.29% | |||
| Average Diluted Shares Outstanding | 0.53% | 10.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||